The research team of Prof. Zhuo Huang found that Carvedilol inhibits neonatal malignant epilepsy caused by KCNT1 mutation, providing new hope for the treatment of refractory epilepsy

Journal of Chinese Pharmaceutical Sciences ›› 2024, Vol. 33 ›› Issue (11): 1092-1094.

• News • Previous Articles Next Articles

The research team of Prof. Zhuo Huang found that Carvedilol inhibits neonatal malignant epilepsy caused by KCNT1 mutation, providing new hope for the treatment of refractory epilepsy

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center

Received:2024-11-25 Revised:2024-11-25 Accepted:2024-11-25 Online:2024-12-10 Published:2024-12-08

Abstract

Supporting:

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center. The research team of Prof. Zhuo Huang found that Carvedilol inhibits neonatal malignant epilepsy caused by KCNT1 mutation, providing new hope for the treatment of refractory epilepsy[J]. Journal of Chinese Pharmaceutical Sciences, 2024, 33(11): 1092-1094.

The research team of Prof. Zhuo Huang found that Carvedilol inhibits neonatal malignant epilepsy caused by KCNT1 mutation, providing new hope for the treatment of refractory epilepsy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 0

Recommended Articles

Metrics

Comments